Research Article

Serum amyloid A and Janus kinase 2 in a mouse model of diabetic kidney disease

Brad P. Dieter¹*, Rick L. Meek¹, Robert J. Anderberg¹, Sheryl K. Cooney¹, Jen L. Bergin¹, Hongyu Zhang², Viji Nair²,³, Matthias Kretzler², Frank C. Brosius²,³, Katherine R. Tuttle¹,⁴

¹ Providence Medical Research Center, Providence Health Care, Spokane, Washington, United States of America, ² Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America, ³ Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan, United States of America, ⁴ Institute of Translational Health Sciences, Kidney Research Institute, Nephrology Division University of Washington, Seattle, Washington, United States of America

* brad.dieter@providence.org

Abstract

Background

Serum amyloid A (SAA), a potent inflammatory mediator, and Janus kinase 2 (JAK2), an intracellular signaling kinase, are increased by diabetes. The aims were to elucidate: 1) a JAK2-mediated pathway for increased SAA in the kidneys of diabetic mice; 2) a JAK2-SAA pathway for inflammation in podocytes.

Methods

Akita diabetic mice (129S6) with podocyte JAK2 overexpression and angiotensin II infusion (4 weeks) were given a JAK1,2 inhibitor (LY03103801, 3 mg/kg/day orally for the last two weeks). Kidneys were immunostained for SAA isoform 3 (SAA3). SAA3 knockout and control mouse podocytes were exposed to advanced glycation end products (AGE) or exogenous SAA with JAK2 inhibition (Tyrphostin AG 490, 50 μM). JAK2 activity (phosphorylation, Western blot, 1 hour) and mRNA for SAA3 and associated inflammatory genes (Cxcl5, Ccl2, and Ccl5) were measured by RT-PCR (20 hours).

Results

SAA3 protein was present throughout the diabetic kidney, and podocyte JAK2 overexpression increased tubulointerstitial SAA3 compared to wild type diabetic controls, 43% versus 14% (p = 0.007); JAK1,2 inhibition attenuated the increase in SAA3 to 15% (p = 0.003). Urine albumin-to-creatinine ratio (r = 0.49, p = 0.03), mesangial index (r = 0.64, p = 0.001), and glomerulosclerosis score (r = 0.51, p = 0.02) were associated with SAA3 immunostaining scores across mouse groups. Exposing podocytes to AGE or exogenous SAA increased JAK2 activity within one hour and mRNA for associated inflammatory genes after 20 hours. JAK2 inhibition reduced SAA3 mRNA expression in podocytes exposed to AGE or SAA. SAA3 knockout podocytes had >85% lower AGE-induced inflammatory genes.
Conclusion

JAK1,2 inhibition reduced SAA and histological features of DKD in podocyte JAK2-overexpressing mice. In podocytes exposed to a diabetes-like condition, JAK2 inhibition reduced expression of SAA, while SAA knockout blocked expression of associated pro-inflammatory mediators. SAA may promote JAK2-dependent inflammation in the diabetic kidney.

Introduction

Pro-inflammatory mediators in the diabetic kidney are induced by activation of various signaling cascades [1–3]. Comparison of transcriptional networks between humans with diabetes and corresponding mouse models identified shared signals in the diabetic kidney [4, 5]. These signals, and their downstream pro-inflammatory mediators, provide candidate targets for new therapeutics for diabetic kidney disease (DKD). Janus kinase 2 (JAK2) is an intracellular tyrosine kinase that transduces cytokine-mediated signals. Compared to non-diabetic individuals, JAK2 is expressed at higher levels in the glomeruli and tubulointerstitium of patients with DKD [5]. In diabetic mice, podocyte-specific JAK2 overexpression exacerbated histological features of DKD and produced a phenotype similar to human DKD [6].

Serum amyloid A (SAA) is a family of acute phase reactants that exert numerous pro-inflammatory actions in many tissues and cells including the kidney [7, 8]. SAA is expressed in mice as acute-phase isoforms 1,2 and 3. Isoforms 1 and 2 are largely homologous (SAA1,2) while isoform 3 (SAA3) is more distinct and highly expressed in the kidney [7, 8]. In non-kidney tissue, SAA expression is up-regulated by JAK signaling. In synovial fibroblasts from the joints of patients with rheumatoid arthritis, JAK2 inhibition abrogated IL-6 induced expression of SAA mRNA [9]. Additionally, a non-specific JAK inhibitor reduced blood levels of SAA and associate pro-inflammatory mediators among patients with rheumatoid arthritis [10, 11]. In humans with advanced diabetic kidney disease, 24 weeks of JAK1/2 inhibition with baricitinib reduced albuminuria by 41% while also reducing circulating levels of SAA and other inflammatory biomarkers [12]. Inflammation is clearly involved in DKD progression, and emerging evidence suggests that increased SAA production in the kidney promotes damage characteristic of DKD [7, 8]. SAA is up-regulated in cells by exposure to diabetes-like conditions (e.g. advanced glycation end products: AGE). Moreover, SAA itself induces pro-inflammatory responses in glomerular podocytes and mesangial cells [7]. Amounts of SAA mRNA are increased in both glomerular and tubulointerstitial compartments in kidneys from patients with DKD compared to non-diabetic glomerular disease and normal controls [7]. SAA protein also associated with histological severity of DKD in patients with both types 1 and 2 diabetes [7]. Similar findings have been observed in two experimental models of DKD, C57BL/6 streptozotocin mice (type 1 diabetic model) and BTBR ob/ob mice (type 2 diabetic model) [7].

Relationships between SAA and JAK2 signaling in the pathophysiology of DKD have not been previously explored. Currently there is a gap in the knowledge of how JAK2 inhibition attenuates inflammation in the diabetic kidney and which downstream effectors are involved. The study aims were to elucidate: 1) a JAK2-mediated pathway for increased SAA in the kidneys of diabetic mice; 2) a JAK2-SAA pathway for inflammation in podocytes.
Methods

Mouse model of diabetes

Podocyte JAK2-overexpressing 129S6 Akita mice (JAK2 mice; S1 Fig) were generated from a previous study and stored samples and data were used for the present study [6]. Non-diabetic wild-type (WT; n = 8) and diabetic WT (n = 8) controls, podocyte JAK2-overexpressing non-diabetic (n = 8) and diabetic (n = 15) male mice were implanted with Alzet osmotic mini-pumps (Model 1004; ALZA Scientific Products, Mountain View, California, USA) at 10 weeks of age [6]. Sterile 0.9% sodium chloride solution containing angiotensin II was infused at a rate of 700 ng/min/kg to accelerate pathologic changes in the kidney and produce a sufficiently severe phenotype for DKD in which to test JAK2 inhibition. Podocyte JAK2-overexpressing non-diabetic mice (n = 4) and diabetic mice (n = 9) also received a JAK1,2 inhibitor (compound LY03103801; Eli Lilly and Company, www.lilly.com) orally at a dose of 3 mg/kg/day in supplemental water (citric acid, pH 3.2) for the last two weeks of the angiotensin II infusion period (S1 Fig). Other mice received only supplemental water at the same volume. Mouse care and procedures were approved by the University of Michigan Committee on the Use and Care of Animals. Veterinary care was provided by the University of Michigan Unit for Laboratory Animal Medicine.

Analytes in mouse urine and serum

Urine and blood samples were collected prior to euthanasia. Blood levels of glycated hemoglobin, triglycerides, and cholesterol were measured by the Michigan Diabetes Research Center Chemistry Laboratory [6]. Serum and urine samples were stored at −70˚C for other assays [6]. Mouse SAA3 was measured by ELISA in serum (Mouse Serum Amyloid A-3 kit, EMD Millipore, www.millipore.com). Urinary albumin concentration was determined by ELISA (Cat. No. 1011, Albuwell, www.exocell.com), and urinary creatinine measurements were performed by a picric acid based assay (www.tecodiagnostics.com).

Histological studies of mouse kidneys

Under general anesthesia, both kidneys were flushed under constant 100 mm Hg pressure with phosphate buffered saline (PBS) containing sodium heparin (50 U/ml) through a cannula placed in the abdominal aorta. The left kidney was ligated while the right kidney was perfused with a ferric oxide slurry for later isolation of glomeruli. The left kidney was removed and weighed. Kidney cortical regions were dissected and snap frozen in liquid nitrogen, or fixed overnight in a solution of 2% paraformaldehyde in PBS. Paraffin-embedded, paraformaldehyde-fixed tissue sections were stained with PAS (periodic acid-Schiff, immunostained with WT-1 antibodies to identify podocytes, and counter-stained with picrosirius red. Fifteen glomeruli per mouse were chosen randomly for quantification of glomerulosclerosis by proportionally scoring areas positive for PAS staining (MetaMorph Imaging Software version 6.1; Molecular Devices Corporation, Downingtown, PA, www.moleculardevices.com) and mesangial index [6].

SAA protein in mouse kidneys

Immunostaining for mouse SAA3 and SAA1,2 proteins were performed with SAA isoform-specific rabbit antibodies [7, 13, 14]. Non-immune rabbit IgG (Sigma Chemical Co, www.sigmaaldrich.com) was used as a negative control. Tissue sections from paraffin-embedded, paraformaldehyde-fixed kidneys were de-paraffinized, hydrated, and subjected to antigen retrieval for 15 minutes at 97˚C in citrate buffer, pH 6.0 (Vector laboratories, Inc.,
Kidney sections were incubated overnight at 4˚ with anti-SAA3 (1:500) or anti-SAA1,2 (1:400) and non-immune rabbit IgG antibodies (5 μg/ml). Bound primary antibodies were detected by incubation with Impress-HRP Reagent (Vector laboratories, Inc.) for one hour at room temperature followed by 3,3’-diaminobenzidine. Kidney tissue sections were counterstained with hematoxylin.

SAA3 Immunostaining was assessed by two masked observers on 4 to 7 mice per group (two kidney sections per mouse) and 5 randomly-selected areas per section for scoring of abundance and intensity. Scoring for tubulointerstitial staining was based on staining area (0, 25, 50, 75, or 100% of visual field) and intensity (0—none; 1—light; 2—medium; and 3—darkest) [7]. The immunostaining score was the product of area and intensity. Scoring for glomerular staining was based on the proportion of positively stained glomeruli from 10 random glomeruli per section and two sections per mouse. Scores of two observers were averaged for a final score for tubulointerstitial and glomerular staining [7].

**RNA analyses in mouse glomeruli**

RNA was harvested using the RNeasy Mini Kit with QIAshredder (Qiagen, www.qiagen.com) from glomeruli of podocyte JAK2-overexpressing diabetic mice (n = 12). Half of these mice (n = 6) had received the JAK1,2 inhibitor and the other half (n = 6) had received vehicle alone for two weeks. Gene expression profiling was performed by the Affymetrix Mouse Gene 2.1 ST platform. Image CEL files were log-transformed, analyzed at the single probe level, and summarized at the gene level with Chip Inspector [5].

**Mouse podocyte cell culture**

Immortalized mouse podocytes (gift from Stuart Shankland, University of Washington) were grown on Collagen I (BD Biosciences, www.bdbiosciences.com) coated Primaria plates (VWR, www.vwrsp.com) in Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma Chemical Company) [15]. Podocytes were grown at 33˚C in media containing 10% heat inactivated fetal bovine serum (Atlas Biologicals Incorporated, www.atlasbio.com) and interferon-gamma (50 units/mL). Cell differentiation was promoted by incubation at 37˚C in media without interferon-gamma for 8 to 10 days. Podocytes tested positive for nephrin by real-time PCR after differentiation. Podocytes were placed on RPMI with reduced fetal bovine serum (0.5%) for one day prior to exposure to exogenous SAA, AGE or control conditions (1 hour for JAK2 activity; 24 hours for mRNA assays). To make AGE-BSA, fatty acid-free fraction IV BSA (Sigma) was incubated with 0.5 M glucose for 45 days at 37˚C. The resulting AGE-BSA solution was dialyzed with phosphate-buffered saline (PBS, pH 7.4) and sterile filtered; endotoxin was undetectable (E-TOXATE, Sigma). For exogenous SAA, recombinant human SAA1 protein (rSAA), (#300–53, PeproTech, www.peprotech.com) was used at 10 μg/mL [7]. AGE-bovine serum albumin was used at 300 μg/mL [7]. The JAK2 inhibitor, Tyrphostin AG 490 (50 μM; LC Laboratories, www.lclabs.com) was added to media along with experimental conditions.

**SAA3 knockout by CRISPR/Cas9 in mouse podocytes**

Knockout of SAA3 in podocytes was achieved by the CRISPR/Cas9 system. One 23-base sgRNA (5’-GAATTGATGCTCGCGGAG-3’) was designed to the target site, exon three of the SAA3 gene (chromosome 7: NC_000073.6; Gene ID: 20210). The sgRNA expression cassette was driven by a U6 promoter. The T7 promoter was added upstream of the Cas9 sequence. mCherry, a fluorescent tag, was engineered into the vector controlled under an Sf40 promoter. All sequences were synthesized by Genecopeia (www.gencopeia.com). Podocytes were transfected according with a Lipofectamine 3000 (Invitrogen, www.thermofisher.com).
protocol at 60% confluency in 6-well plates with 340 ng/μL of plasmid and 1.5 μL Lipofectamine 3000. After 48 hours of transfection, cells seeded on coverslips were examined for mCherry expression by confocal microscopy (Leica SPE Confocal Microscope, www.leica-microsystems.com) to assess uptake of plasmid. After confirmation of suitable transfection, cells were placed on neomycin-containing (500 ng/μL) medium for 10 days. Neomycin-resistant colonies were passaged using serial dilutions into 60 mm dishes. After 72 hours, individual colonies were selected using cloning rings for culture in 60 mm dishes and non-neomycin containing media. Gene knockout was verified by the absence of SAA3 mRNA (real-time PCR) and SAA3 protein in the media (ELISA) after exposure to AGE (S2 Fig).

**Western blot for JAK2 and phosphorylated-JAK2 in mouse podocytes**

Cell lysates were prepared from podocytes grown in 60 mm dishes. Cells were washed and scraped from the plate with ice cold PBS. Podocytes were pelleted by centrifugation at 1000 x g for 10 minutes. The cell pellets were lysed in RIPA buffer (50 mM Tris pH 8.0, 150 mM sodium chloride, 0.5 mM ethylenediaminetetraacetic acid, 1 mM dithiothreitol, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate) containing HALT protease and phosphatase inhibitors (Pierce, www.thermoscientific.com). Soluble cell lysates were denatured in reducing sodium dodecyl sulfate sample buffer at 95˚C for 5 minutes. Samples were electrophoresed through denaturing sodium dodecyl sulfate-polyacrylamide gels (4 to 20% gradient, Bio-Rad) and proteins were transferred to nitrocellulose membranes. The membranes were blocked in Tris-hydrochloric acid buffered saline, pH 7.2, containing 0.05% Tween 20, and 5% non-fat dry milk, for one hour and then incubated with primary antibodies overnight at 4˚C at 1:1000 dilutions (JAK2 #D2E12; phosphorylated-JAK2 #C80C3, Cell Signaling Technology, www.cellsignal.com). Bound antibodies were detected with horseradish peroxidase-conjugated anti-rabbit IgG (Cell Signaling Technology), followed by detection using SuperSignal West Chemiluminescent Substrate (Pierce). Digitized images were analyzed using a Chemidoc Touch Imaging system and Image Lab software version 5.2.1 (BioRad Laboratories, www.bio-rad.com).

**RNA analyses for SAA3 and inflammatory mediators in mouse podocytes**

Total podocyte RNA was isolated and DNase-I-treated by the RNAqueousmicro kit (ThermoFisher, www.thermoscientific.com). RNA was quantified using the Quant-iTRiboGreen RNA Reagent and kit (ThermoFisher). cDNA was synthesized from equal amounts of RNA using Superscript III (ThermoFisher). Expression of mRNA for SAA3, C-X-C motif chemokine ligand 5 (Cxc5), C-C motif chemokine ligand 2 (Ccl2) and C-C motif chemokine ligand 5 (Ccl5) was measured by quantitative real-time PCR on an Applied Biosystems 7900HT Fast RT-PCR System using SA Biosciences SYBR Green reagent (ThermoFisher) Gene amplification results were quantified with Sequence Detection System v2.4 software (Applied Biosystems) and normalized to mouse TATA-box binding protein.

**Statistical analysis**

Data were assessed for normality using the Shapiro-Wilk test and verified using a Q-Q plot. Data for the urinary albumin-to-creatinine ratio (UACR) was log-transformed for analysis and back-transformed for data presentation. Analysis of variance was used to evaluate differences between groups for normally distributed data: mouse body weight, log UACR, and JAK2 and phosphorylated-JAK2 protein. Tukey’s honest significant difference test was used for multiple comparisons of positive F-tests. Pairwise Wilcoxon rank sum tests with Hommel adjusted p-values were used for non-normally distributed data: blood levels of glycated hemoglobin,
total cholesterol, triglycerides; kidney tissue mesangial index and SAA immunostaining score; and mRNA expression data from podocyte experiments. The Significance Analysis of Microarrays method that utilizes a false discovery rate-controlling procedure to generate q values was utilized for the glomerular RNA data generated from microarrays [16]. The threshold for statistical significance for all analyses in this study were set at a significance level of \( p < 0.05 \). Statistical analyses were conducted using R version 3.12 and Chip Inspector.

**Results**

**Characteristics of diabetic and non-diabetic mice**

Diabetic mice weighed less and had higher blood levels of glycated hemoglobin, total cholesterol, and triglycerides. JAK2 overexpression did not significantly affect these parameters (Table 1). Diabetes increased the UACR, but JAK2 overexpression did not significantly increase it. Treatment with the JAK1,2 inhibitor lowered UACR and the mesangial index in JAK2 mice (Fig 1).

**SAA in the kidneys and blood of diabetic and non-diabetic mice**

Kidney mRNA and protein for SAA3 along with serum SAA3 were analyzed to determine the effect of diabetes and JAK2 overexpression at the tissue and systemic levels, respectively. Diabetic JAK2 mice had quantifiably greater SAA3 protein in the tubulointerstitium compared to diabetic WT controls, 43% versus 14%. JAK1,2 inhibition attenuated the increases in SAA3 in JAK2 diabetic mice (15%, Fig 2). Differences in SAA3 protein in the glomeruli were not present by diabetes status or JAK2 overexpression (Fig 2). With JAK1,2 inhibition, SAA3 in the glomeruli of the JAK2 diabetic mice was similar to control WT diabetic and non-diabetic mice (Fig 2).

RNA was harvested from micro-dissected glomeruli of a subset of diabetic JAK2 mice that received either supplemental water (n = 6) or the JAK1,2 inhibitor (n = 6). In the diabetic JAK2 mice, JAK1,2 inhibition reduced SAA3 mRNA by 50% (q <0.01, n = 6 for each group) compared to the JAK2 diabetic mice that did not receive the inhibitor.

Across mouse groups, SAA3 protein levels in the kidney correlated with indicators of glomerular damage: UACR, mesangial index, and glomerulosclerosis score, (Fig 3). Plasma SAA3 was not increased by diabetes or JAK2 overexpression (Fig 4).

**SAA and JAK2 signaling and inflammation in mouse podocytes**

Exposure to AGE or SAA for 1 hour significantly increased JAK2 phosphorylation (Fig 5). Exposure to AGE or exogenous SAA significantly increased expression of SAA3 mRNA (Fig 6). Exposure of podocytes to exogenous SAA also significantly increased mRNA expression of

---

**Table 1.** Body weight, glycemia, and lipids in mice.

|                      | Non-Diabetic | Diabetic |
|----------------------|--------------|----------|
|                      | Wild Type    | JAK2     | p-value\(^a\) | Wild Type | p-value\(^a\) | JAK2     | p-value\(^a\) | p-value\(^b\) |
| Body Weight (g)      | 26 ± 2       | 26 ± 1   | 0.95       | 21 ± 2    | <0.001     | 23 ± 2   | 0.025     | 0.27       |
| Glycated Hemoglobin (%) | 5 ± 0      | 5 ± 0    | 0.99       | 12 ± 2    | <0.001     | 13 ± 2   | <0.001    | 0.94       |
| Total Cholesterol (mg/dL) | 109 ± 5    | 112 ± 9  | 0.99       | 244 ± 108 | <0.001     | 168 ± 50 | 0.27      | 0.10       |
| Triglycerides (mg/dL)  | 90 ± 32      | 59 ± 16  | 0.42       | 137 ± 47  | 0.13       | 173 ± 66 | 0.004     | 0.38       |

\(^a\) versus non-diabetic wild-type  
\(^b\) versus diabetic wild-type
Fig 1. Albuminuria and structural markers of kidney damage in mice. A) UACR and B) mesangial index scores from non-diabetic and diabetic mice from wild type (WT) and podocyte specific JAK2-overexpressing mice with and without the JAK1,2 inhibitor. WT non-diabetic control (n = 3), JAK2 non-diabetic control (n = 4), JAK2 non-diabetic + JAK1,2 inhibitor (n = 4), WT diabetic control (n = 6), JAK2 diabetic control (n = 6), and JAK2 diabetic + JAK1,2 inhibitor (n = 9).

https://doi.org/10.1371/journal.pone.0211555.g001
Cxcl5, Ccl2, and Ccl5, while JAK2 inhibition significantly inhibited expression of Cxcl5 and Ccl2 but not Ccl5 (Fig 6). Control and SAA3 knockout podocytes were exposed to AGE for 20 hours. Knockout of SAA3 in podocytes significantly inhibited AGE-induced expression of SAA3, Cxcl5, Ccl2, and Ccl5 by greater than 85% (Fig 7).

Fig 2. Mouse kidney immunostaining for SAA3 protein. Representative sections of non-diabetic and diabetic mouse kidneys from both wild type (WT) and podocyte specific JAK2-overexpressing mice with and without the JAK1,2 inhibitor. Magnification bars are shown in the lower right corner of each image. (B) SAA3 quantification by immunostaining scores in tubulointerstitium and (C) in glomeruli. WT non-diabetic control (n = 3), JAK2 non-diabetic control (n = 4), JAK2 non-diabetic with inhibitor (n = 4), WT diabetic control (n = 4), JAK2 diabetic control (n = 6), and JAK2 diabetic with JAK1,2 inhibitor (n = 9).

https://doi.org/10.1371/journal.pone.0211555.g002
Fig 3. Associations of SAA protein with features of diabetic kidney disease. SAA protein was measured by the quantification of immunostaining and relationship were determined for albuminuria (UACR), mesangial index (mesangial expansion), and glomerulosclerosis (PAS stained area) score. Mouse groups: WT Control (n = 3), JAK2 control (n = 4), JAK1,2 inhibitor (n = 4), WT diabetic control (n = 4), JAK2 diabetic control (n = 6) JAK2 diabetic with JAK1,2 inhibitor (n = 9).

https://doi.org/10.1371/journal.pone.0211555.g003
**Fig 4.** SAA3 protein concentrations in mouse plasma by diabetes and JAK2 status with or without the JAK1,2 inhibitor. Wild type (WT) control (n = 3), JAK2 control (n = 4), WT diabetic control (n = 4), WT diabetic + JAK1,2 inhibitor (n = 4), JAK2 diabetic control (n = 6) JAK2 diabetic + JAK1,2 inhibitor (n = 9).

https://doi.org/10.1371/journal.pone.0211555.g004

**Fig 5.** The effect of exposure to AGE and exogenous SAA on JAK2 activity. Podocytes were exposed to AGE or SAA for 1 hour. A) Representative Western blot showing phosphorylated and non-phosphorylated JAK2 (C: control sample). B) Quantitative data from Western blots showing effect of exposure to either AGE or SAA on JAK2 phosphorylation (n = 3 for each condition).

https://doi.org/10.1371/journal.pone.0211555.g005
Discussion

Podocyte JAK2 overexpression in diabetes independently and synergistically increased SAA in the mouse kidney, which directly correlated with glomerular damage. Exposure to AGE or
SAA activated JAK2 signaling to produce a pro-inflammatory response in podocytes, while knockout of SAA3 had a profound inhibitory effect on expression of JAK2-associated inflammatory mediators. Taken together, the present data show SAA to be a downstream mediator of JAK2 that may mechanistically contribute to podocyte-derived inflammation and consequent kidney damage in diabetes.

Fig 7. The effect of podocyte SAA3 knockout on AGE-induced SAA3 Cxcl5, Ccl2 and Ccl5 mRNA. Control and SAA3 knockout (KO) podocytes were exposed to AGE for 20 hours. n = 5 for each condition.

https://doi.org/10.1371/journal.pone.0211555.g007
SAA3 protein was present in the tubulointerstitium and glomeruli of diabetic mice and increased by podocyte JAK2 overexpression. Non-diabetic mice did not have detectable SAA3 in the kidney except with podocyte JAK2 overexpression. In contrast, there was nominal immunostaining in the mouse kidneys for SAA1,2, the main systemic isoforms of SAA (S2 Fig). The present findings of SAA3 protein in the kidneys of this mouse model of type 1 diabetes expand our previous findings of robust amounts of SAA3 in the C57BL/6 streptozotocin type 1 diabetes model and the BTBR ob/ob type 2 diabetes model of DKD [7]. These data also correspond to the kidney-expressed human SAA isoform in patients with DKD due to either type 1 or type 2 diabetes [7]. JAK1,2 inhibition attenuated the amount of SAA3 protein in the tubulointerstitium of diabetic mice and JAK2 diabetic and non-diabetic mice. Furthermore, JAK1,2 inhibition reduced SAA3 mRNA expression by approximately 50% in glomeruli from diabetic JAK2 mice. In sum, locally-produced SAA3, rather than systemic SAA 1,2, is the primary isoform present in the diabetic mouse kidney [7].

Blood levels of SAA3 were not different between diabetic mice and their controls in the present study in contrast to previous observations [7]. This may be due to the infusion of angiotensin II, which induces expression of SAA3 in non-kidney tissues, and in this way, may increase systemic levels to mitigate between group differences [17]. However, despite similar levels of systemic SAA3 across experimental groups, marked increases in SAA3 protein in the kidneys of diabetic and/or podocyte JAK2-overexpressing mice are consistent with local production. These data support earlier findings that SAA3 is highly expressed in the mouse kidney and contributes minimally to circulating SAA [7, 14, 18]. Additionally, the present observations suggest that urine, a direct effluent from the kidney, may be a better sample source than blood to potentially target for SAA biomarker development [19, 20].

This study advances the understanding of how JAK2 is involved in the pathogenesis of DKD by identifying a particular downstream mediator, namely SAA and an associated inflammatory response. JAK2 is expressed at greater levels in the tubulointerstitium and glomeruli of humans with DKD compared to non-diabetic controls. Enhanced expression of JAK2 specifically in podocytes markedly augmented the DKD phenotype in the present model of type 1 diabetes in mice [5, 6]. In cultured podocytes, exogenous SAA induced JAK2 activity and SAA3 overexpression along with associated inflammatory mediators. Inhibition of JAK2 activity in podocytes reduced the AGE or exogenous SAA-induced expression of SAA3 and corresponding inflammatory mediators. Notably, SAA3 knockout in podocytes abolished AGE-induced expression of JAK2-upregulated inflammatory mediators. As such, increased SAA appears to be both a consequence and a cause of JAK2 signaling, and therefore, may drive a “feed forward” loop that leads to a broad inflammatory response.

Exposure of cultured podocytes to AGE, a diabetes-like condition, increased JAK2 activity and induced expression of SAA3 as well as pro-inflammatory mediators including Cxcl5, Cc12, and Ccl5. In particular, Cc12 is a central chemokine for tissue macrophage recruitment. A link between local SAA production and Cc12 expression has been observed in other mouse models [21–23]. For example, in C57BL/6 mice fed a pro-inflammatory diet (high-fat, high-sucrose), knockout of SAA3 attenuated increases in Cc12 expression and macrophage accumulation in visceral adipose tissue compared to control C57BL/6 mice fed the same diet [24]. Local production of SAA3 also induces Cc12 and inflammation in adipose tissue of ob/ob mice [22]. Inhibition of JAK2 did not reduce SAA-induced CCL5, suggesting that there are JAK2 independent mechanisms by which inflammation is regulated. In sum, these data support the overall concept that local SAA expression is causal for tissue inflammation.

The present study integrates understanding of inflammation in DKD mediated by JAK signaling and SAA, thereby, identifying a novel mechanistic pathway. JAK2 is known to be up-regulated in the kidneys of humans with DKD. Independent work demonstrated both
increased expression of SAA mRNA and protein associated with histological injury in the kidneys of humans with DKD [5,7]. In a randomized controlled clinical trial of patients with advanced DKD, administration of a JAK1/2 inhibitor reduced systemic levels of SAA with concurrent reductions in albuminuria. Thus, there is therapeutic evidence for JAK1/2 regulation of SAA in humans with DKD [12]. The present data provide further evidence that a JAK2-SAA pathway may be involved with direct effects on the kidney. Furthermore, JAK2-induced SAA may be responsible for driving a panoply of additional inflammatory mediators.

An inherent limitation of this study is that a mouse model does not fully replicate human DKD. However, podocyte JAK2 overexpression produced a more “humanized” representation of the diabetic kidney [6]. Moreover, the cross-species comparison of glomerular gene expression profiles between mice and humans provided a unique opportunity to determine the role of JAK2 and SAA in DKD. Specifically, the murine SAA3 gene is locally expressed in the kidney [25]. Mouse SAA3 is most comparable across sequence similarity, tissue expression, and biological function to the SAA isoforms found in the human diabetic kidney [26]. Therefore, the demonstration of local expression of SAA3 in the mouse diabetic kidney may allow translation of these findings into understanding the role of kidney-specific SAA isoforms in human DKD. Another limitation of the present study is that we did not observe significant increases in glomerular staining by JAK2 overexpression, the compartment in which JAK2 overexpression occur. However, we did see changes in the tubulointerstitial, which may indicate that our measurements were not sensitive enough to detect changes in immunostaining in the glomerular compartment. The use of AGEs in the in vitro studies is also a limitation as it does not fully recapitulate the in vivo environment, which also includes high glucose, high insulin, and myriad inflammatory mediators. However, the use of AGEs has shown to be a robust model of inducing inflammation in resident glomerular cells, specifically the expression of SAA [7,8].

In conclusion, SAA, a potent pro-inflammatory mediator, was uniquely present and increased in the kidneys of diabetic mice and further augmented by podocyte JAK2 overexpression. Inhibition of the JAK1,2 pathway ameliorated histological features of DKD in this mouse model. JAK2-dependent inflammatory mechanisms associated with diabetes were mediated by SAA in podocytes. Further investigation of JAK2-SAA associated inflammatory networks represent a promising area for therapeutic and biomarker development in DKD.

Supporting information
S1 Table. Primer sequences.
(DOCX)

S1 Fig. Depiction of target vector used to create podocyte JAK2 overexpressing mice and experimental protocol.
(DOCX)

S2 Fig. The effect of AGE exposure on SAA3 protein levels in wild-type and SAA knockdown cells. Wild type and SAA3 knockdown cells were exposed to AGE for 24 hours and media was harvested and analyzed for SAA3 protein content by ELISA. n = 3 for each condition.
(DOCX)

S3 Fig. Mouse kidney immunostaining for SAA1,2. A) Representative sections of non-diabetic and diabetic mouse kidneys from wild type (WT) and JAK2 mice +/- the JAK1,2
inhibitor (LY03103801). B) Positive control for SAA1,2 antibody in kidneys from control and lipopolysaccharide (LPS) injected mice after 20 hours. Images taken at 20x.

(S4 Fig. Expression of WT-1 mRNA in podocytes. Podocytes were differentiated and kept in culture for 7 days post differentiation and WT-1 mRNA levels were measured using RT-qPCR.

(S5 Fig. Expression of SAA3 mRNA in microdissected glomeruli. RNA was harvested from glomeruli of podocyte JAK2-overexpressing diabetic mice who received vehicle (n = 6) or the JAK1,2 inhibitor (n = 6). Gene expression profiling was performed by the Affymetrix Mouse Gene 2.1 ST platform.

(S1 File. Manuscript data.

Acknowledgments

Portions of this paper were presented as an oral abstract at the 2016 American Society of Nephrology Meeting.

Author Contributions

Conceptualization: Brad P. Dieter, Rick L. Meek, Hongyu Zhang, Matthias Kretzler, Frank C. Brosius, Katherine R. Tuttle.

Data curation: Brad P. Dieter, Rick L. Meek, Jen L. Bergin.

Formal analysis: Brad P. Dieter, Rick L. Meek, Robert J. Anderberg, Sheryl K. Cooney, Jen L. Bergin, Hongyu Zhang, Viji Nair.

Funding acquisition: Matthias Kretzler, Frank C. Brosius.

Investigation: Brad P. Dieter, Rick L. Meek, Robert J. Anderberg, Sheryl K. Cooney, Matthias Kretzler, Frank C. Brosius.

Methodology: Brad P. Dieter, Rick L. Meek, Robert J. Anderberg, Hongyu Zhang, Matthias Kretzler, Frank C. Brosius, Katherine R. Tuttle.

Project administration: Brad P. Dieter, Hongyu Zhang.

Resources: Brad P. Dieter, Hongyu Zhang, Katherine R. Tuttle.

Supervision: Brad P. Dieter, Katherine R. Tuttle.

Visualization: Brad P. Dieter, Jen L. Bergin.

Writing – original draft: Brad P. Dieter, Katherine R. Tuttle.

Writing – review & editing: Brad P. Dieter, Rick L. Meek, Robert J. Anderberg, Sheryl K. Cooney, Jen L. Bergin, Hongyu Zhang, Viji Nair, Matthias Kretzler, Frank C. Brosius, Katherine R. Tuttle.

References

1. Mezzano S, Aros C, Droguett A, Burgos ME, Ardiles L, Flores C, et al. NF-kappaB activation and over-expression of regulated genes in human diabetic nephropathy. *Nephrol Dial Transplant*, 19: 2505–2512, 2004. https://doi.org/10.1093/ndt/gfh207 PMID: 15280531
2. Woroniecka KL, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K. Transcriptome analysis of human diabetic kidney disease. *Diabetes*, 60: 2354–2369, 2011. https://doi.org/10.2337/db10-1181 PMID: 21752957

3. Tuttle KR. Linking metabolism and immunity: diabetic nephropathy is an inflammatory disease. *J Am Soc Nephrol*, 16: 1537–1538, 2005. https://doi.org/10.1681/ASN.2005040393 PMID: 15872083

4. Hodgin JB, Nair V, Zhang H, Randolph A, Harris RC, Nelson RG, et al. Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. *Diabetes*, 62: 299–308, 2013. https://doi.org/10.2337/db11-1667 PMID: 23139354

5. Berthier CC, Zhang H, Schin M, Henger A, Nelson RG, Yee B, et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. *Diabetes*, 58: 469–477, 2009. https://doi.org/10.2337/db08-1328 PMID: 19017763

6. Zhang H, Nair V, Saha J, Atkins KB, Hodgin JB, Saunders TL, et al. Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice. *Kidney Int*, 2017.

7. Anderberg RJ, Meek RL, Hudkins KL, Alpers CE, Leboeuf RC, et al. Serum amyloid A and inflammation in diabetic kidney disease and podocytes. *Lab Invest*, 95: 250–262, 2015. https://doi.org/10.1038/labinvest.2014.163 PMID: 25531567

8. Meek RL, Leboeuf RC, Saha SA, Alpers CE, Hudkins KL, Cooney SK, et al. Glomerular cell death and inflammation with high-protein diet and diabetes. *Nephrol Dial Transplant*, 28: 1711–1720, 2013. https://doi.org/10.1093/ndt/gfs579 PMID: 23314315

9. Migita K, Izumi Y, Jiuchi Y, Kozuru H, Kawahara C, Izumi M, et al. Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis. *Clin Exp Immunol*, 175: 208–214, 2014. https://doi.org/10.1111/cei.12234 PMID: 24665995

10. Migita K, Koga T, Komori A, Torigoshi T, Maeda Y, Izumi Y, et al. Influence of Janus kinase inhibition on interleukin-6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium. *J Rheumatol*, 38: 2309–2317, 2011. https://doi.org/10.3899/jrheum.101362 PMID: 21844139

11. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isof orm real-time quantitative RT-PCR assay system. *Biochem Biophys Res Commu*, 314: 363–369, 2004.

12. Tuttle KR, Brosius FC, Adler SG, Kretzler M, Metha RL, Tumlin JA, et al. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. *Nephrol Dial Transplant*. 2018:1–10.

13. Meek RL, Eriksen N, Benditt EP. Murine serum amyloid A3 is a high density apolipoprotein and is secreted by macrophages. *Proc Natl Acad Sci U S A*, 89: 7949–7952, 1992. PMID: 15181819

14. Hoffman JS, Benditt EP. Secretion of serum amyloid protein and assembly of serum amyloid-protein-rich high density lipoprotein in primary mouse hepatocyte culture. *J Biol Chem*, 257: 10518–10522, 1982. PMID: 6809750

15. Shankland SJ, Pippin JW, Reiser J, Mundel P. Podocytes in culture: past, present, and future. *Kidney Int*, 72: 26–36, 2007. https://doi.org/10.1038/sj.ki.5002291 PMID: 17457377

16. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci U S A*, 98: 5116–5121, 2001. https://doi.org/10.1073/pnas.091062498 PMID: 11309499

17. Zhang L, Du J, Hu Z, Han G, Delafontaine P, Garcia, et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. *J Am Soc Nephrol*, 20: 604–612, 2009. https://doi.org/10.1681/ASN.2008060628 PMID: 19158350

18. Chiba T, Han CY, Vaisar T, Shimokado K, Kargi A, Chen MH, et al. Serum amyloid A3 does not contribute to circulating SAA levels. *J Lipid Res*, 50: 1353–1362, 2009. https://doi.org/10.1194/jlr.M900089-JLR200 PMID: 19286646

19. Dieter EP, McPherson SM, Afkarian M, de Boer IH, Mehrotra R, Short R, et al. Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease. *J Diabetes Complications*, 2016.

20. Saulnier PJ, Dieter EP, Tanamas SK, McPherson SM, Wheelock KM, Kowlier WC, et al. Association of Serum Amyloid A with Kidney Outcomes and All-Cause Mortality in American Indians with Type 2 Diabetes. *Am J Nephrol*, 46: 276–284, 2017. https://doi.org/10.1159/000481269 PMID: 28934744

21. Badolato R, Wang JM, Murphy WJ, Lloyd AR, Michiel DF, Bausserman LL, et al. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. *J Exp Med*, 180: 203–209, 1994. PMID: 7516407

22. Mullan RH, Bresnihan B, Golden-Mason L, Markham T, O’Hara R, FitzGerald O, et al.: Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in...
rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. *Arthritis Rheum*, 54: 105–114, 2006. https://doi.org/10.1002/art.21518 PMID: 16385502

23. Han CY, Subramanian S, Chan CK, Omer M, Chiba T, Wight TN, et al.: Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion. *Diabetes*, 56: 2260–2273, 2007. https://doi.org/10.2337/db07-0218 PMID: 17563062

24. den Hartigh LJ, Wang S, Goodspeed L, Ding Y, Averill M, Subramanian S, et al. Deletion of serum amyloid a3 improves high fat high sucrose diet-induced adipose tissue inflammation and hyperlipidemia in female mice. *PLoS One*, 9: e108564, 2014. https://doi.org/10.1371/journal.pone.0108564 PMID: 25251243

25. Meek RL, Benditt EP. Amyloid A gene family expression in different mouse tissues. *J Exp Med*, 164: 2006–2017, 1986. PMID: 3783088

26. Thaler R, Sturmlechner I, Spitzer S, Riester SM, Rumpler M, Zwerina J, et al. Acute-phase protein serum amyloid A3 is a novel paracrine coupling factor that controls bone homeostasis. *FASEB*, 29: 1344–1359, 2015.